Provention Bio yesterday closed its initial public offering, raising approximately $63.9 million.
Funds from the round will help support the Oldwick, N.J.-based company’s clinical-stage biopharmaceuticals that aim to prevent or intercept immune-mediated diseases.
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.